These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1151769)

  • 21. Pharmacodynamics and antithrombotic effects after intravenous administration of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Depin JC; Vigié A; Chavernac G; Rousselot C; Lardy C; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1203-7. PubMed ID: 7848332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cilostazol on platelet aggregation and experimental thrombosis.
    Kimura Y; Tani T; Kanbe T; Watanabe K
    Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats].
    Xu HL; Feng YP
    Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. II: Effects on the cardiovascular system and smooth muscle organs.
    Osada E; Murai T; Ishizaka Y; Sanai K
    Arzneimittelforschung; 1984; 34(11A):1641-51. PubMed ID: 6152157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
    Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
    Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
    Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM
    J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
    Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
    Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
    J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
    Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.
    Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE
    Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological properties of the novel anti-platelet aggregating agent 4-cyano-5,5-bis(4-methoxyphenyl)-4-pentenoic acid.
    Fujimori T; Harada K; Saeki T; Kogushi M; Akasaka K; Yamagishi Y; Yamatsu I
    Arzneimittelforschung; 1987 Oct; 37(10):1143-8. PubMed ID: 3124862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
    Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
    J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
    Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
    J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfonyliminoimidazolidines, a new class of oral hypoglycemic agents. 4. Toxicity and general pharmacology of 1-[p-[2-(crotonylamino)-ethyl]-phenylsulfonyl]-3-cyclohexy l-2-imino- imidazolidine (CGP 11 112).
    Märki F; Büch O; Delini-Stula A; Kraetz J; Petermann H; Radeke E; Schweizer A; Thomann P; Truog A
    Arzneimittelforschung; 1984; 34(3):247-52. PubMed ID: 6539603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
    Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
    J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.